{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=81", "query": { "condition": "Non-Small Cell Lung Cancer, Small Cell Lung Cancer", "page": 81 }, "page_size": 10 }, "pagination": { "page": 81, "page_size": 10, "total_count": 3681, "total_pages": 369, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=82&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=80&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T15:44:37.495Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00858403", "title": "Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2009-03", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2014-01-15", "last_synced_at": "2026-11-05T15:44:37.495Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00858403" }, { "nct_id": "NCT00324805", "title": "Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage IB Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIB Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Vinorelbine Tartrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1501, "start_date": "2007-07-19", "completion_date": "2025-01-31", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-11-05T15:44:37.495Z", "location_count": 1139, "location_summary": "Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 712 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324805" }, { "nct_id": "NCT01746251", "title": "Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Afatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2013-01", "completion_date": "2021-11", "has_results": false, "last_update_posted_date": "2020-07-07", "last_synced_at": "2026-11-05T15:44:37.495Z", "location_count": 4, "location_summary": "Palo Alto, California • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01746251" }, { "nct_id": "NCT07195695", "title": "Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Zongertinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2026-01-16", "completion_date": "2036-09-02", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-05T15:44:37.495Z", "location_count": 28, "location_summary": "Fresno, California • Glendale, California • Orange, California + 22 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07195695" }, { "nct_id": "NCT01951157", "title": "A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Lurbinectedin (PM01183)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 69, "start_date": "2013-09-11", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-11-05T15:44:37.495Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951157" }, { "nct_id": "NCT02130427", "title": "A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Biopsy Proven Non Small Cell Lung Cancer", "Head and Neck Cancer", "Gastrointestinal Cancer", "Colorectal Cancer", "Rectal Cancers", "Gynecological Malignancy Requiring Definitive Radiotherapy" ], "interventions": [ { "name": "CT scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2010-09", "completion_date": "2022-04", "has_results": true, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-11-05T15:44:37.495Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02130427" }, { "nct_id": "NCT01074177", "title": "Understanding Mechanisms of Acquired Resistance to BIBW2992", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non-small Cell Lung Cancer", "EGFR Mutations" ], "interventions": [ { "name": "BIBW 2992", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2011-02", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2018-03-09", "last_synced_at": "2026-11-05T15:44:37.495Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074177" }, { "nct_id": "NCT04303780", "title": "Study to Compare AMG 510 \"Proposed INN Sotorasib\" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "KRAS p, G12c Mutated /Advanced Metastatic NSCLC" ], "interventions": [ { "name": "AMG 510", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 345, "start_date": "2020-06-04", "completion_date": "2026-06-24", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-11-05T15:44:37.495Z", "location_count": 54, "location_summary": "Anaheim, California • Duarte, California • Long Beach, California + 46 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04303780" }, { "nct_id": "NCT03854227", "title": "A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "PF-06939999 dose escalation", "type": "DRUG" }, { "name": "PF-06939999 monotherapy", "type": "DRUG" }, { "name": "PF-06939999 in combination with docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2019-03-14", "completion_date": "2022-04-27", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-11-05T15:44:37.495Z", "location_count": 22, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Pasadena, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03854227" }, { "nct_id": "NCT04902872", "title": "Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Epithelial Ovarian Cancer", "Small Cell Lung Carcinoma", "Breast Cancer", "Colorectal Cancer", "Pancreas Cancer", "Appendix Cancer", "Non-small Cell Lung Cancer", "Gastric Cancer", "Esophagus Cancer", "Urothelial Carcinoma", "Sarcoma" ], "interventions": [ { "name": "CBX-12", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cybrexa Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2021-05-03", "completion_date": "2025-06-24", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-05T15:44:37.495Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Austin, Texas • Houston, Texas + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04902872" } ] }